10月20日 - ** 药物开发商Replimune集团REPL.O的股票盘前上涨73.6%至7.81美元
** 该公司称，美国食品和药物管理局（FDA）已接受该公司重新提交的实验性疗法RP1与百时美施贵宝BMY.N的Opdivo联用治疗晚期黑色素瘤的申请。
** 美国食品和药物管理局将于 4 月 10 日前对该药物做出决定
** 该公司于今年 7 月收到了 FDA 的完全响应函 (link)，理由是没有足够的数据证明其实质性疗效。
** 截至上一交易日收盘，股价累计下跌 62.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.